Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 24.6% in March

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 4,610,000 shares, a growth of 24.6% from the February 28th total of 3,700,000 shares. Currently, 5.7% of the shares of the company are short sold. Based on an average trading volume of 1,440,000 shares, the days-to-cover ratio is presently 3.2 days.

Institutional Trading of Compass Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CMPX. Tower Research Capital LLC TRC increased its stake in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after buying an additional 12,917 shares during the period. Independent Advisor Alliance bought a new stake in shares of Compass Therapeutics during the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $27,000. Intech Investment Management LLC purchased a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $30,000. Finally, Mariner LLC bought a new position in Compass Therapeutics in the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on CMPX. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Jefferies Financial Group upped their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $4.00 to $6.00 in a research note on Wednesday. Finally, Guggenheim reissued a “buy” rating and set a $12.00 target price on shares of Compass Therapeutics in a research note on Wednesday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.63.

Compass Therapeutics Stock Down 24.6 %

Shares of NASDAQ:CMPX opened at $1.69 on Thursday. The firm has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $2.11. The stock has a market capitalization of $233.70 million, a P/E ratio of -4.57 and a beta of 1.19. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.